Home Cart Sign in  
Chemical Structure| 5184-64-5 Chemical Structure| 5184-64-5

Structure of ESI-05
CAS No.: 5184-64-5

Chemical Structure| 5184-64-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ESI 05 is an inhibitor of EPAC2. It can inhibit cAMP binding to EPAC2 and cAMP mediated EPAC2 guanine nucleotide exchange factor (GEF) activity (IC50 = 0.4 μM).

Synonyms: NSC 116966

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ESI-05

CAS No. :5184-64-5
Formula : C16H18O2S
M.W : 274.38
SMILES Code : O=S(C1=CC=C(C)C=C1)(C2=C(C)C=C(C)C=C2C)=O
Synonyms :
NSC 116966
MDL No. :MFCD00091573
InChI Key :CGPHOZWFSFNOEQ-UHFFFAOYSA-N
Pubchem ID :272513

Safety of ESI-05

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of ESI-05

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NRK49F cells 3 μmol/L 1 hour To investigate the inhibitory effect of ESI-05 on TGF-β1-induced α-SMA expression PMC6349209
HEK293/EPAC2 cells 1, 5, 10, 25 μM 5 minutes ESI-05 dose-dependently inhibited 007-AM-induced Rap1 activation PMC3494926
HEK293/EPAC1 cells 25 μM 5 minutes ESI-05 had no inhibitory effect on EPAC1 PMC3494926
NAc slices 20 µM 40 minutes To investigate the effect of Epac2 inhibitor ESI-05 on dopamine release, results showed that ESI-05 blocked the S-220-induced increase in dopamine release PMC9436413
Human pancreatic α-cells 25μM 90 minutes Inhibition of EPAC2 significantly reduced adrenaline-induced [Ca2+]i increase and glucagon secretion PMC6258900
Mouse pancreatic α-cells 25μM 90 minutes Inhibition of EPAC2 significantly reduced adrenaline-induced [Ca2+]i increase and glucagon secretion PMC6258900

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Epac2 conditional knockout mice Intraperitoneal injection 3.3 or 10 mg/kg Single injection, tested 10 minutes later To investigate the effect of Epac2 inhibition on cocaine self-administration, results showed that ESI-05 dose-dependently reduced cocaine intake PMC9436413
Mice High-fat diet-induced obesity model Intracerebroventricular injection 0.2 nmol/brain/day Once daily for 14 days ESI-05 significantly reversed leptin resistance and reduced body weight and food intake in HFD-induced obese mice. PMC5024738
Mice Epac WT, Epac1–/–, Epac2–/–, and Epac1&2–/– mice Intraperitoneal injection 5 μM 15 minutes ESI-05 significantly decreased ENaC activity in Epac WT mice on a sodium-deficient diet but had no significant effect on mice on a regular diet. PMC8855822
Adult female Sprague Dawley rats Spinal cord contusion model Intrathecal administration 15 µM Continuous for 1 week To investigate the role of EPAC2 in NPC transplantation-mediated treatment mechanisms for SCI. Results showed that NPC transplantation combined with ESI-05 treatment increased rostral cAMP levels but reduced EPAC2 mRNA levels, increased scar area, polarized microglia into an inflammatory phenotype, and enlarged the gap between NeuN+ cells. PMC9338125

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.64mL

0.73mL

0.36mL

18.22mL

3.64mL

1.82mL

36.45mL

7.29mL

3.64mL

References

 

Historical Records

Categories